

ScopeSys Announces CAD\$1.5 million Seed Financing to Accelerate Single-Molecule Analytics for Genetic Medicines

Funding supports development and commercial launch of ScopeSys' first benchtop analytics system for genetic medicines

Vancouver, BC, April 28, 2026: ScopeSys Inc., a life sciences analytics company advancing single-molecule imaging and analytics of genetic medicines, today announced the closing of a CAD\$1.5 million (USD\$1.1 million) seed financing round. The round included participation from UBC Venture Funds, Hextwo Capital, WUTIF, VentureUs, Xavaav Capital, and several angel investors in Canada and the United States.

ScopeSys is commercializing a powerful imaging and analytics platform built on its proprietary Convex Lens-induced Confinement (CLiC) technology, which enables real-time, quantitative, single-molecule and single-particle measurements. The company is currently supporting biopharma partners through collaborative research projects generating deep characterization data for mRNA lipid nanoparticles (LNPs) and other complex genetic medicines, helping our partners accelerate formulation development, improve process scale-up, and generate structured datasets for AI model training and validation.

Proceeds from the financing will be used to accelerate development and commercial launch of ScopeSys' first benchtop analytics system including the ScopeTop™ instrument and LNP specific consumable to bring high-resolution, single-particle analytics into routine drug discovery and development workflows. ScopeSys is also scaling its analytical services and broadening its R&D portfolio of biologically relevant, market-driven applications.

“Genetic medicines are becoming more complex, and drug developers need analytical tools that better measure drug loading, molecular arrangement, dynamic interactions and subpopulation heterogeneity with far greater precision than conventional methods allow,” said Padma Kodukula, Chief Executive Officer of ScopeSys. “This financing helps position ScopeSys to bring CLiC technology to the market through instruments, consumables, and services, making advanced analytics more accessible to drug developers enabling faster, better-informed decisions across the drug development value chain.”

Padma Kodukula PhD, MBA, Chief Executive Officer, ScopeSys

“CLiC opens a fundamentally new window into biological and biomedical systems by enabling quantitative measurements on individual molecules, particles, and live cells under relevant conditions,” said Dr. Sabrina Leslie, Co-founder and Board Member of ScopeSys. “We are excited to enable direct measurements of critical biophysical parameters of drugs at the single-molecule level and their relationship to therapeutic outcomes, as well as to translate this scientific advancement into robust tools which can be used by developers to improve medicines for patients.”

Sabrina Leslie PhD, ScopeSys Founder

ScopeSys' platform enables quantitative, high-resolution analysis of individual particles and sub-populations in solution, providing insights beyond conventional ensemble methods and with improved sensitivity, data richness, and lower bias than existing single-molecule methods. The company is focused on helping drug developers measure drug loading, structure, heterogeneity, and particle behavior across key stages of drug discovery, process scale-up and manufacturing. By offering benchtop instrumentation, application-specific consumables, and analytical services, ScopeSys is building a scalable analytics platform designed to become a critical partner to companies developing the next generation of medicines.

About ScopeSys

ScopeSys is a life sciences analytics company developing and commercializing instruments, consumables, and services powered by our proprietary single-molecule imaging and analytics platform to advance the design, development, and manufacturing of genetic medicines.